ResearcherUniversitätsmedizin RostockActive in the last 2 years
Yixuan Ma
Matched on ORCID iD 0000-0001-8156-4091; OpenAlex author ID A5070744146. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 8
2022: 3 papers · 2023: none · 2024: 1 paper
Papers 4
- Sex Matters-Insights from Testing Drug Efficacy in an Animal Model of Pancreatic Cancer. Co-author DOI 10.3390/cancers16101901↗
- Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines. Co-author DOI 10.3390/cancers14184467↗
- The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines. Co-author DOI 10.3390/ijms23084295↗
- Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell L… Co-author DOI 10.3390/ijms23084409↗
Closest collaborators
The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Dietmar Zechner · 4 shared papers, 2022–2024 · strength 0.59
- Paper Sex Matters-Insights from Testing Drug Efficacy in an Animal Model of Pancreatic Cancer. DOI 10.3390/cancers16101901↗
- Paper Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Li… DOI 10.3390/cancers14184467↗
- Paper The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Panc… DOI 10.3390/ijms23084295↗
- Hugo Murua Escobar · 4 shared papers, 2022–2024 · strength 0.59
- Paper Sex Matters-Insights from Testing Drug Efficacy in an Animal Model of Pancreatic Cancer. DOI 10.3390/cancers16101901↗
- Paper Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Li… DOI 10.3390/cancers14184467↗
- Paper The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Panc… DOI 10.3390/ijms23084295↗
- Frank Ulrich Weiß · 3 shared papers, 2022 · strength 0.40
- Paper Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Li… DOI 10.3390/cancers14184467↗
- Paper The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Panc… DOI 10.3390/ijms23084295↗
- Paper Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in… DOI 10.3390/ijms23084409↗
- Markus M. Lerch · 3 shared papers, 2022 · strength 0.40
- Paper Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Li… DOI 10.3390/cancers14184467↗
- Paper The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Panc… DOI 10.3390/ijms23084295↗
- Paper Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in… DOI 10.3390/ijms23084409↗
- Benjamin Schulz · 2 shared papers, 2022–2024 · strength 0.33
- Tim Schreiber · 1 shared paper, 2024 · strength 0.20
- Brigitte Vollmar · 1 shared paper, 2024 · strength 0.20
- Robert Jaster · 1 shared paper, 2022 · strength 0.14
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.